Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Overview | 9 | 1 |
| Therapeutics Development | 10 | 2 |
| Pipeline Products for Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Overview | 10 | 1 |
| Pipeline Products for Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Comparative Analysis | 11 | 1 |
| Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics under Development by Companies | 12 | 1 |
| Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics under Investigation by Universities/Institutes | 13 | 1 |
| Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Pipeline Products Glance | 14 | 2 |
| Clinical Stage Products | 14 | 1 |
| Early Stage Products | 15 | 1 |
| Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Products under Development by Companies | 16 | 1 |
| Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Products under Investigation by Universities/Institutes | 17 | 1 |
| Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Companies Involved in Therapeutics Development | 18 | 11 |
| Abeona Therapeutics, Inc. | 18 | 1 |
| Alexion Pharmaceuticals, Inc. | 19 | 1 |
| ArmaGen Inc. | 20 | 1 |
| Axcentua Pharmaceuticals AB | 21 | 1 |
| BioMarin Pharmaceutical Inc. | 22 | 1 |
| Dorphan S.A. | 23 | 1 |
| Laboratorios Del Dr. Esteve S.A. | 24 | 1 |
| Lysogene | 25 | 1 |
| Shire Plc | 26 | 1 |
| Swedish Orphan Biovitrum AB | 27 | 1 |
| UniQure N.V. | 28 | 1 |
| Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics Assessment | 29 | 9 |
| Assessment by Monotherapy Products | 29 | 1 |
| Assessment by Target | 30 | 2 |
| Assessment by Mechanism of Action | 32 | 2 |
| Assessment by Route of Administration | 34 | 2 |
| Assessment by Molecule Type | 36 | 2 |
| Drug Profiles | 38 | 23 |
| ABO-101 - Drug Profile | 38 | 1 |
| Product Description | 38 | 1 |
| Mechanism of Action | 38 | 1 |
| R&D Progress | 38 | 1 |
| ABO-102 - Drug Profile | 39 | 1 |
| Product Description | 39 | 1 |
| Mechanism of Action | 39 | 1 |
| R&D Progress | 39 | 1 |
| AGT-184 - Drug Profile | 40 | 1 |
| Product Description | 40 | 1 |
| Mechanism of Action | 40 | 1 |
| R&D Progress | 40 | 1 |
| AMT-110 - Drug Profile | 41 | 1 |
| Product Description | 41 | 1 |
| Mechanism of Action | 41 | 1 |
| R&D Progress | 41 | 2 |
| AXP-10711 - Drug Profile | 43 | 1 |
| Product Description | 43 | 1 |
| Mechanism of Action | 43 | 1 |
| R&D Progress | 43 | 2 |
| BMN-250 - Drug Profile | 45 | 1 |
| Product Description | 45 | 1 |
| Mechanism of Action | 45 | 1 |
| R&D Progress | 45 | 1 |
| EGT-101 - Drug Profile | 46 | 1 |
| Product Description | 46 | 1 |
| Mechanism of Action | 46 | 1 |
| R&D Progress | 46 | 1 |
| EGT-201 - Drug Profile | 47 | 1 |
| Product Description | 47 | 1 |
| Mechanism of Action | 47 | 1 |
| R&D Progress | 47 | 1 |
| LYSSAF-301 - Drug Profile | 48 | 1 |
| Product Description | 48 | 1 |
| Mechanism of Action | 48 | 1 |
| R&D Progress | 48 | 2 |
| LYSSAF-302 - Drug Profile | 50 | 1 |
| Product Description | 50 | 1 |
| Mechanism of Action | 50 | 1 |
| R&D Progress | 50 | 1 |
| Proteins for Sanfilippo Syndrome - Drug Profile | 51 | 1 |
| Product Description | 51 | 1 |
| Mechanism of Action | 51 | 1 |
| R&D Progress | 51 | 1 |
| Recombinant N-Acetylgalactosamine-6-Sulfatase Replacement for Mucopolysaccharidosis Type IIID - Drug Profile | 52 | 1 |
| Product Description | 52 | 1 |
| Mechanism of Action | 52 | 1 |
| R&D Progress | 52 | 1 |
| SBC-103 - Drug Profile | 53 | 1 |
| Product Description | 53 | 1 |
| Mechanism of Action | 53 | 1 |
| R&D Progress | 53 | 1 |
| SHP-610 - Drug Profile | 54 | 1 |
| Product Description | 54 | 1 |
| Mechanism of Action | 54 | 1 |
| R&D Progress | 54 | 1 |
| Small Molecule for Sanfilippo Syndrome - Drug Profile | 55 | 1 |
| Product Description | 55 | 1 |
| Mechanism of Action | 55 | 1 |
| R&D Progress | 55 | 1 |
| Small Molecule to Target Alpha-N-Acetylglucosaminidase for MPSIIIB - Drug Profile | 56 | 1 |
| Product Description | 56 | 1 |
| Mechanism of Action | 56 | 1 |
| R&D Progress | 56 | 1 |
| SOBI-003 - Drug Profile | 57 | 1 |
| Product Description | 57 | 1 |
| Mechanism of Action | 57 | 1 |
| R&D Progress | 57 | 1 |
| Stem Cell Therapy for Mucopolysaccharidosis Type IIIA - Drug Profile | 58 | 1 |
| Product Description | 58 | 1 |
| Mechanism of Action | 58 | 1 |
| R&D Progress | 58 | 1 |
| Stem Cell Therapy for Sanfilippo Syndrome - Drug Profile | 59 | 1 |
| Product Description | 59 | 1 |
| Mechanism of Action | 59 | 1 |
| R&D Progress | 59 | 1 |
| Stem Cell Therapy to Activate NAG for Mucopolysaccharidosis III - Drug Profile | 60 | 1 |
| Product Description | 60 | 1 |
| Mechanism of Action | 60 | 1 |
| R&D Progress | 60 | 1 |
| Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Recent Pipeline Updates | 61 | 7 |
| Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) - Dormant Projects | 68 | 1 |
| Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Product Development Milestones | 69 | 5 |
| Featured News &Press Releases | 69 | 1 |
| May 24, 2016: Abeona Therapeutics Announces FDA Allowance of Investigational New Drug for Phase 1/2 Clinical Study With ABO-101 Gene Therapy for Patients With Sanfilippo Syndrome Type B (MPS IIIB) | 69 | 1 |
| Feb 25, 2016: ESTEVE Provides Update On EGT-101 For Sanfilippo A Syndrome | 70 | 1 |
| Feb 25, 2016: ESTEVE Provides Update On EGT-201 For Sanfilippo B Syndrome | 70 | 1 |
| Jan 11, 2016: Abeona Therapeutics Announces Initial European Regulatory Approval for Phase 1/2 Gene Therapy Clinical Study for Patients With Sanfilippo Syndrome | 71 | 1 |
| May 20, 2015: PlasmaTech Biopharmaceuticals Announces Orphan Drug and Rare Pediatric Disease Designations For ABX-101 From FDA | 72 | 1 |
| Apr 02, 2014: Orphan designation granted for MPSIII | 72 | 1 |
| Jul 25, 2013: New stem cell gene therapy gives hope to prevent inherited neurological disease | 72 | 1 |
| Apr 11, 2013: Axcentua granted patent on ten solid forms of genistein | 73 | 1 |
| Appendix | 74 | 2 |
| Methodology | 74 | 1 |
| Coverage | 74 | 1 |
| Secondary Research | 74 | 1 |
| Primary Research | 74 | 1 |
| Expert Panel Validation | 74 | 1 |
| Contact Us | 74 | 1 |
| Disclaimer | 75 | 1 |